Following recent updates from the Phase II SCOPE study, notably the strength of the PFS data and selection of iSCIB1+ for future development, the focus remains on accelerating plans to start a registrational global late-stage trial in advanced melanoma in 2026. Importantly, discussions have now been scheduled with regulators in the US, UK and Europe, a key step to gain the necessary approvals to initiate the trial; a pre-IND meeting with the FDA is planned for this year. In parallel, active discussions are also ongoing with potential partners to optimise the development path.
Scancell: Trinity Delta
Sep 11, 2025Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.